checkAd

Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO for the Treatment of ALS

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO (sodium phenylbutyrate and taurursodiol) for the treatment of adults with amyotrophic lateral sclerosis (ALS). RELYVRIO (previously known as AMX0035 in the U.S.) significantly slowed the loss of physical function in people living with ALS in a randomized, placebo-controlled clinical trial. RELYVRIO can be taken as a monotherapy or with existing approved treatments.

“Today’s FDA approval of RELYVRIO is an exciting milestone for the ALS community and is a major step toward achieving our mission to one day end the suffering caused by neurodegenerative diseases,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. “We want to give a heartfelt thank you to the broader ALS community, including healthcare professionals and those living with ALS, for their guidance, support of our clinical programs, and for sharing their experiences with us. Their stories inspired us and helped our team to better understand the ALS clock, instilling in us a deep sense of urgency that will continue to drive us forward. This is just the beginning and there is much more to be done.”

ALS is a relentlessly progressive and fatal neurodegenerative disorder caused by motor neuron death in the brain and spinal cord. Motor neuron loss in ALS leads to deteriorating muscle function, the inability to move and speak, respiratory paralysis and eventually, death. More than 90% of people with ALS have sporadic disease, showing no clear family history. ALS affects approximately 29,000 people in the U.S.

Leading U.S. ALS advocacy organizations including The ALS Association, Answer ALS Foundation, I AM ALS, Les Turner ALS Foundation and Team Gleason said in a statement, “Our organizations have been on a mission to create a world free of ALS. With today’s approval, we are encouraged that RELYVRIO can offer people living with ALS and their families the potential of more time with functional independence. This is especially important for a rapidly progressive disease with a median survival time from diagnosis of just two to three years. This is significant for people living with ALS, their loved ones, caregivers, clinicians, researchers, and advocacy, as we now have a new treatment option that could be a big step forward for the future of ALS care.”

Seite 1 von 6




0 Kommentare
Nachrichtenquelle: Business Wire (engl.)
 |  174   |   |   

Schreibe Deinen Kommentar

Disclaimer

Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO for the Treatment of ALS Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO (sodium phenylbutyrate and taurursodiol) for the treatment of adults with amyotrophic …

Nachrichten des Autors

103 Leser
100 Leser
72 Leser
64 Leser
51 Leser
38 Leser
20 Leser
14 Leser
14 Leser
14 Leser
443 Leser
329 Leser
200 Leser
187 Leser
173 Leser
161 Leser
154 Leser
148 Leser
146 Leser
140 Leser
1142 Leser
745 Leser
589 Leser
515 Leser
498 Leser
475 Leser
463 Leser
443 Leser
411 Leser
398 Leser
7528 Leser
2918 Leser
2428 Leser
2378 Leser
2155 Leser
2102 Leser
1787 Leser
1699 Leser
1586 Leser
1533 Leser